Deals21 Jan 2026, 04:13 pm
CORONA Remedies Secures Prestigious EAEU-GMP Certification, Opens Doors to $25 Billion Market
AI Summary
CORONA Remedies Limited has announced its successful accreditation with the Eurasian Economic Union (EAEU) Good Manufacturing Practices (GMP) certification. This certification paves the way for CORONA’s entry into five EAEU member nations under a B2B business model, unlocking access to a pharmaceutical market estimated at USD 25 billion. The certification aligns with CORONA’s long-term vision of fostering sustainable international partnerships and strengthens its focus across its four key therapeutic pillars— Women'’s Health, Cardio-Diabetes, Pain Management, and Urology.
Key Highlights
- CORONA Remedies Limited secures EAEU-GMP certification
- Unlocks access to a $25 billion pharmaceutical market
- Opens doors to five EAEU member nations under a B2B business model
- Strengthens CORONA’s focus on four key therapeutic pillars
- Reflects CORONA’s commitment to quality healthcare and global regulatory standards